scholarly journals Severe factor V deficiency: exon skipping in the factor V gene causing a partial deletion of the C1 domain

2003 ◽  
Vol 1 (6) ◽  
pp. 1237-1244 ◽  
Author(s):  
R. Asselta ◽  
M. C. Montefusco ◽  
S. Duga ◽  
M. Malcovati ◽  
F. Peyvandi ◽  
...  
2021 ◽  
Vol 22 (18) ◽  
pp. 9705
Author(s):  
Sara Bernal ◽  
Irene Pelaez ◽  
Laura Alias ◽  
Manel Baena ◽  
Juan A. De Pablo-Moreno ◽  
...  

Factor V is an essential clotting factor that plays a key role in the blood coagulation cascade on account of its procoagulant and anticoagulant activity. Eighty percent of circulating factor V is produced in the liver and the remaining 20% originates in the α-granules of platelets. In humans, the factor V gene is about 80 kb in size; it is located on chromosome 1q24.2, and its cDNA is 6914 bp in length. Furthermore, nearly 190 mutations have been reported in the gene. Factor V deficiency is an autosomal recessive coagulation disorder associated with mutations in the factor V gene. This hereditary coagulation disorder is clinically characterized by a heterogeneous spectrum of hemorrhagic manifestations ranging from mucosal or soft-tissue bleeds to potentially fatal hemorrhages. Current treatment of this condition consists in the administration of fresh frozen plasma and platelet concentrates. This article describes the cases of two patients with severe factor V deficiency, and of their parents. A high level of mutational heterogeneity of factor V gene was identified, nonsense mutations, frameshift mutations, missense changes, synonymous sequence variants and intronic changes. These findings prompted the identification of a new mutation in the human factor V gene, designated as Jaén-1, which is capable of altering the procoagulant function of factor V. In addition, an update is provided on the prospects for the treatment of factor V deficiency on the basis of yet-to-be-developed recombinant products or advanced gene and cell therapies that could potentially correct this hereditary disorder.


1996 ◽  
Vol 75 (01) ◽  
pp. 045-048 ◽  
Author(s):  
B Lunghi ◽  
L Iacoviello ◽  
D Gemmati ◽  
M G Dilasio ◽  
E Castoldi ◽  
...  

SummaryThree novel polymorphisms were found in the repeated region of the large exon 13 of factor V gene, one giving rise to a codon dimorphism (Serl240) and two causing aminoacid substitutions (Hisl299Arg, Leul257Ile). An increasing frequency of the Argl299 (R2 allele) correlated with a decreasing mean plasma factor V activity in the groups of subjects under study, which included 26 unrelated subjects with partial factor V deficiency. Family studies supported the co-inheritance both of low factor V activity and of R2 allele. The reduction of factor V activity associated with the R2 allele was not clinically symptomatic even in the homozygous condition and was characterized by a parallel reduction of antigen in plasma, in which abnormal molecules were not detected. Data suggest that the R2 allele represents a marker in linkage with an unknown defect rather than a functional polymorphism.These studies provide the first evidence of a genetic component in determining factor V levels in plasma and of a genetic linkage between the factor V gene and factor V deficiency. They also define specific haplotypes which are associated with factor V deficiency or with APC resistance (Arg506Gln) and are valuable fools for the study of factor V defects.


2000 ◽  
Vol 111 (4) ◽  
pp. 1240-1246 ◽  
Author(s):  
Maria Claudia Montefusco ◽  
Stefano Duga ◽  
Rosanna Asselta ◽  
Elena Santagostino ◽  
Giacomo Mancuso ◽  
...  

2001 ◽  
Vol 114 (4) ◽  
pp. 871-874 ◽  
Author(s):  
Richard Van Wijk ◽  
Maria Claudia Montefusco ◽  
Stefano Duga ◽  
Rosanna Asselta ◽  
Wouter Van Solinge ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2151-2151
Author(s):  
Jaewoo Song ◽  
Hyun-Sook Kim ◽  
Singyoung Kim ◽  
Jong-Rak Choi ◽  
Yoo-Hong Min ◽  
...  

Abstract Coagulation factor V acts as the cofactor of activated factor X of prothrombinase complex is composed of six domains which are A1, A2, B, A3, C1, C2 arranged from N to C-terminal. Crystalography of C2 domain has been reported along with its three spike-like structures at the base which are important for interaction with phospholipids. But the functional importance of C1 domain which closely resembles C2 domain largely remains unidentified. We have experienced a family with hereditary factor V deficiency whose proband was a compound heterozygote of in-frame deletion located to domain C1 and truncating mutation of domain B. The proband was 25 year old male who suffered from bleeding after tooth extraction. Prothrombin time and activated partial thromboplastin time were both prolonged (35.7 sec, 111.7 sec respectively), and coagulation factor activities were all normal except for factor V which was 4%. The factor V antigen level measured by ELISA method was 3%. We sought for mutations of factor V gene by PCR direct sequencing targeting whole coding region. A truncating mutation (3481C>T, R1133X) was found in exon 13, where most of the other mutations have been reported. It has already been reported by Van Wijk et al. in 2001. The same mutation was found in his twin brother (factor V activity 5%) but in only one of two sisters exhibiting partial deficiency (factor V activity, 45% and 50% and antigen level, 25% and 37% each). In addition In-frame deletion (nt 6026 del 6 bp, corresponding to deletion of N1982, S1983) in C1 domain was also found in the proband and also in his twin brother and one sister who has not R1133X explaining the partial deficiency in two sisters each possessing different mutations. The putative structural and functional importance of N1982, S1983 was sought by examining protein model based on the crystal structure of bovine factor Va that is inactivated by protein C. N1982, S1983 are located on a loop region that is exposed on surface of domain C1 and have close contact with another loop in A3 domain. This model suggests the possibility that N1982 and S 1983 contribute to maintaining the stable conformation attributable to hydrogen bond formation between K1980 and N1986 of domain C1 with D1604 of domain A3. Mutations implicated in hereditary factor V deficiency involving domains other than A or B are mostly located in or affect the integrity of C2 domain. To the best of our knowledge only five mutations involving C1 domain have been reported till now. Four were truncating mutations and splicing error resulting in gross abnormality in protein structure. One missense mutation in this domain was reported to be subject to increased intracellular degradation. R1985A near to N1982 and A1983 also caused decreased factor V level in scanning mutagenesis study. The novel in-frame deletion can also be susceptible to accelerated degradation. And the in-frame deletion in our patient may also result in unstable factor 5 structure which enhances intracellular degradation. But the possibility of functional defect including decreased phospholipid binding or attenuated cofactor function due to incorrect positioning of domain A3 relative to domain C1, cannot be ruled out and should be further investigated.


Haemophilia ◽  
2006 ◽  
Vol 12 (2) ◽  
pp. 172-178 ◽  
Author(s):  
N. YAMAKAGE ◽  
M. IKEJIRI ◽  
K. OKUMURA ◽  
A. TAKAGI ◽  
T. MURATE ◽  
...  

1998 ◽  
Vol 101 (1) ◽  
pp. 32-39 ◽  
Author(s):  
Joan F. Guasch ◽  
Suzanne Cannegieter ◽  
Pieter H. Reitsma ◽  
Elizabeth T. Van 't Veer-Korthof ◽  
Rogier M. Bertina

2000 ◽  
Vol 111 (4) ◽  
pp. 1240-1246 ◽  
Author(s):  
Maria Claudia Montefusco ◽  
Stefano Duga ◽  
Rosanna Asselta ◽  
Elena Santagostino ◽  
Giacomo Mancuso ◽  
...  

1996 ◽  
Vol 75 (02) ◽  
pp. 270-274 ◽  
Author(s):  
Benget Zöller ◽  
Johan Holm ◽  
Peter Svensson ◽  
Björn Dahlbäck

SummaryInherited resistance to activated protein C (APC-resistance), caused by a point mutation in the factor V gene leading to replacement of Arg(R)506 with a Gin (Q), and inherited protein S deficiency are associated with functional impairment of the protein C anticoagulant system, yielding lifelong hypercoagulability and increased risk of thrombosis. APC-resistance is often an additional genetic risk factor in thrombosis-prone protein S deficient families. The plasma concentration of prothrombin fragment 1+2 (F1+2), which is a marker of hyper-coagulable states, was measured in 205 members of 34 thrombosis-prone families harbouring the Arg506 to Gin mutation (APC-resistance) and/or inherited protein S deficiency. The plasma concentration of F1+2 was significantly higher both in 38 individuals carrying the FV:Q506 mutation in heterozygous state (1.7 ± 0.7 nM; mean ± SD) and in 48 protein S deficient cases (1.9 ± 0.9 nM), than in 100 unaffected relatives (1.3 ±0.5 nM). Warfarin therapy decreased the F1+2 levels, even in those four patients who had combined defects (0.5 ± 0.3 nM). Our results agree with the hypothesis that individuals with APC-resistance or protein S deficiency have an imbalance between pro- and anti-coagulant forces leading to increased thrombin generation and a hypercoagulable state.


1997 ◽  
Vol 78 (05) ◽  
pp. 1419-1420 ◽  
Author(s):  
Tetsuo Ozawa ◽  
Kenji Niiya ◽  
Naoko Ejiri ◽  
Nobuo Sakuragawa

Sign in / Sign up

Export Citation Format

Share Document